Laura Esserman, MD, MBA, an internationally recognized breast surgeon, breast oncology specialist and visionary in personalized medicine, is revolutionizing breast cancer screening and treatment.
She has received numerous awards, has led many large multi-center grants, is an international speaker, and has published over 200 scientific articles.
Since 2002 Dr. Esserman has led the I-SPY TRIALS, a ground breaking national public-private collaboration among NCI, FDA, more than 20 cancer research centers and major pharma and biotech companies. The I-SPY 2 Trial combines biomarker-based personalized medicine with adaptive trial design in a neo-adjuvant setting, in order to significantly reduce the cost and time to bring safe and effective new drugs to market for patients who need them most. This trial model has now become an international model for translational research.
Dr. Esserman is now working to determine whether breast cancer screening that is personalized to each woman, based on her individual risk factors, is safer and more effective than standard annual mammograms. To answer this big question, she sought and was awarded a $14.1 million grant by the Patient-Centered Outcomes Research Institute (PCORI) for a programmatic adaptive trial of 100,000 women comparing annual vs. risk-based screening for the WISDOM Study. Importantly, she is using a multi-stakeholder model, to repurpose the resources in the systems to drive innovation and create health care value. Participants will be drawn from another of her major initiatives, the Athena Breast Health Network, a University of California-wide initiated breast cancer research and treatment consortium.